Engineered dialdehyde dextran/quaternized chitosan hydrogel incorporating myricetin nanoparticles for diabetic oral...

Conventional management of diabetic mouth ulcers often demonstrates limited efficacy. Primary obstacles to recovery encompass microbial colonization, damage from reactive oxygen species, and deficient blood vessel development. To meet this significant clinical challenge, an injectable hydrogel biomaterial termed DQM1 has been developed, specifically designed for promoting tissue regeneration in diabetic oral wounds. This composite construct comprises an interconnected polysaccharide network combining dialdehyde dextran and quaternized chitosan, strengthened through myricetin nanoparticles generated via magnesium ion-driven myricetin self-assembly. Post-injection, DQM1 rapidly establishes a protective hydrogel barrier. The dressing demonstrates potent antimicrobial activity coupled with effective scavenging of detrimental reactive species. Collective actions transform the injury environment from a chronically inflamed state to an active rebuilding phase. A significant benefit involves inherent post-treatment biodegradability, guaranteeing complete elimination after fulfilling its regenerative function. Outcomes from laboratory studies and animal models demonstrate that DQM1 markedly enhances oral mucosal wound healing. As an innovative therapeutic platform, such hydrogel-based technology presents considerable potential as a solution for diabetic oral lesions, thereby improving patient prognoses in this complex disorder.